Award Data

DESCRIPTION (provided by applicant): Advancement in wound management or tissue repair has been limited by the complexities, costs and limited efficacy of purified recombinant growth factors. Further, the combination of these recombinant proteins for moresophisticated approaches is complicated by the need for separate biologics. Optimally, we can move to a single biologic DNA pro-drug that provide ...

DESCRIPTION (provided by applicant): Heparin and its derivatives block P- and L-selectin mediated metastatic spread of cancer in animal models, and they potently inhibit the matrix degrading enzyme heparanase. Moreover, several large clinical trials performed with heparin or low molecular weight heparin have shown that survival is significantly improved by daily subcutaneous administration of hepa ...

DESCRIPTION (provided by applicant): This Phase I application requests funds to support the continued preclinical evaluation of a novel opioid analgesic, PPL-103, and the synthesis and initial preclinical evaluation of a series of new analogs thereof.PPL-103, a potent analgesic, has undergone early preclinical studies by Phoenix PharmaLabs, Inc. (PPL), the applicant organization, and NIDA. PPL ...

DESCRIPTION (provided by applicant): Chronic gingival inflammation afflicts over half of all American adults and can progress to periodontal disease, eventually resulting in tooth loss. Periodontitis is initiated by bacterial infection of the gingival tissues through a subgingival microbial biofilm on the tooth surface that releases bacterial lipopolysaccharide (LPS) and other antigens. In turn, L ...

DESCRIPTION (provided by applicant): We seek to develop an ultra-fast, zinc-free insulin analog formulation for the treatment of diabetes mellitus. An ultra-fast pharmacokinetic-dynamic (PK/PD) profile promises to enable superior performance of pump therapy (continuous subcutaneous insulin infusion) with enhanced safety and more robust integration with glucose- sensing technologies. Ultra-fast kin ...

DESCRIPTION (provided by applicant): If successful, this program will result in an assay chip that collects, stabilizes, and accurately quantifies a suite of biomarkers indicative of renal injury. Its sensitivity and accuracy may enable it to detect slowlyoccurring renal damage. Its multianalyte capability could distinguish different mechanisms of renal damage. It should be adaptable to automated ...

DESCRIPTION (provided by applicant): Painful bladder syndrome/interstitial cystitis (PBS/IC) is an indolent bladder disorder that has continued to be a debilitating disease with few truly effective treatment options. Inflammatory conditions that afflict the urinary bladder can lead to pelvic pain, debilitating urinary symptoms, bladder fibrosis, recurring urinary infection, and renal failure. We h ...

DESCRIPTION (provided by applicant): Antiscatter grids currently employed on fluoroscopic systems are limited in their capability to control scatter. As a result, fluoroscopic radiation levels are higher for the average patient than they would be with a more efficient grid system, and higher still for large patients. Poor image quality often increases the beam-on time required to successfully perf ...

DESCRIPTION (provided by applicant): The US Center for Disease Control (CDC) estimates that more than 1.7 million healthcare associated infections (HAI) are acquired in US hospitals every year, resulting in approximately 100,000 deaths and adding 30-40 billion of direct treatment expense to the nation's healthcare costs (1). Microbial pathogens from tap water are a significant source of HAI ...

DESCRIPTION (provided by applicant): Central vision field loss (CFL) is caused by inherited and acquired diseases that irreversibly damage the fovea while leaving the peripheral retina relatively intact. CFL results in 1,700,000 legal blindness and lowvision (LV) cases in the US. LV rehabilitation is the means of restoring functional abilities modified by CFL so that the patient's quality ...